Ryuichi Morishita

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Topics

Ischemia Reperfusion Injury

Basal Cell Carcinoma

Top Venues

Nature communications

BioMed research international

This page only lists publications with an associated author ORCID identifier.

Publications

Munehisa Shimamura, Hiroki Hayashi, Nan Ju, Shota Yoshida, Satoshi Baba, Tsutomu Sasaki, Hideki Mochizuki, Ryuichi Morishita, Hironori Nakagami
R-spondin 3/LGR4 (Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4) Axis Is a Novel Inflammatory and Neurite Outgrowth Signaling System in the Ischemic Brain in Mice. Stroke (2023)
Munehisa Shimamura, Hiroki Hayashi, Nan Ju, Shota Yoshida, Satoshi Baba, Tsutomu Sasaki, Hideki Mochizuki, Ryuichi Morishita, Hironori Nakagami
R-spondin 3/LGR4 (Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4) Axis Is a Novel Inflammatory and Neurite Outgrowth Signaling System in the Ischemic Brain in Mice. Stroke 54 (6) (2023)
Masayoshi Suda, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Naomi Matsumoto, Yutaka Yoshida, Ryuta Mikawa, Akihiro Katayama, Jun Wada, Masahide Seki, Yutaka Suzuki, Atsushi Iwama, Hironori Nakagami, Ayako Nagasawa, Ryuichi Morishita, Masataka Sugimoto, Shujiro Okuda, Masanori Tsuchida, Kazuyuki Ozaki, Mayumi Nakanishi-Matsui, Tohru Minamino
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging 1 (12) (2021)
Masayoshi Suda, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Naomi Matsumoto, Yutaka Yoshida, Ryuta Mikawa, Akihiro Katayama, Jun Wada, Masahide Seki, Yutaka Suzuki, Atsushi Iwama, Hironori Nakagami, Ayako Nagasawa, Ryuichi Morishita, Masataka Sugimoto, Shujiro Okuda, Masanori Tsuchida, Kazuyuki Ozaki, Mayumi Nakanishi-Matsui, Tohru Minamino
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging 1 (12) (2021)
Masayoshi Suda, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Naomi Matsumoto, Yutaka Yoshida, Ryuta Mikawa, Akihiro Katayama, Jun Wada, Masahide Seki, Yutaka Suzuki, Atsushi Iwama, Hironori Nakagami, Ayako Nagasawa, Ryuichi Morishita, Masataka Sugimoto, Shujiro Okuda, Masanori Tsuchida, Kazuyuki Ozaki, Mayumi Nakanishi-Matsui, Tohru Minamino
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging 1 (12) (2021)
Masayoshi Suda, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Naomi Matsumoto, Yutaka Yoshida, Ryuta Mikawa, Akihiro Katayama, Jun Wada, Masahide Seki, Yutaka Suzuki, Atsushi Iwama, Hironori Nakagami, Ayako Nagasawa, Ryuichi Morishita, Masataka Sugimoto, Shujiro Okuda, Masanori Tsuchida, Kazuyuki Ozaki, Mayumi Nakanishi-Matsui, Tohru Minamino
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging 1 (12) (2021)
Masayoshi Suda, Ippei Shimizu, Goro Katsuumi, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Naomi Matsumoto, Yutaka Yoshida, Ryuta Mikawa, Akihiro Katayama, Jun Wada, Masahide Seki, Yutaka Suzuki, Atsushi Iwama, Hironori Nakagami, Ayako Nagasawa, Ryuichi Morishita, Masataka Sugimoto, Shujiro Okuda, Masanori Tsuchida, Kazuyuki Ozaki, Mayumi Nakanishi-Matsui, Tohru Minamino
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging 1 (12) (2021)
Shota Yoshida, Hironori Nakagami, Hiroki Hayashi, Yuka Ikeda, Jiao Sun, Akiko Tenma, Hideki Tomioka, Tomohiro Kawano, Munehisa Shimamura, Ryuichi Morishita, Hiromi Rakugi
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nature communications 11 (1) (2020)
Munehisa Shimamura, Hironori Nakagami, Hideo Shimizu, Kouji Wakayama, Tomohiro Kawano, Yuka Ikeda, Hiroki Hayashi, Shota Yoshida, Hideki Mochizuki, Ryuichi Morishita
Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. BioMed research international 2018 (2018)